Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 450

1.

"Big Sister" Wisdom: How might non-Indigenous speech-language pathologists genuinely, and effectively, engage with Indigenous Australia?

McDermott D.

Int J Speech Lang Pathol. 2019 Jun;21(3):252-262. doi: 10.1080/17549507.2019.1617896. Epub 2019 Jun 10.

PMID:
31181968
2.

Holt-Oram Syndrome.

McDermott DA, Fong JC, Basson CT.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2004 Jul 20 [updated 2019 May 23].

3.

Dynamic phases, stratification, laning, and pattern formation for driven bidisperse disk systems in the presence of quenched disorder.

McDermott D, Yang Y, Reichhardt CJO, Reichhardt C.

Phys Rev E. 2019 Apr;99(4-1):042601. doi: 10.1103/PhysRevE.99.042601.

PMID:
31108701
4.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
5.

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Gao X, McDermott DF, Michaelson MD.

Oncologist. 2019 Jun;24(6):725-727. doi: 10.1634/theoncologist.2019-0165. Epub 2019 Apr 29. No abstract available.

PMID:
31036769
6.

Plerixafor for the Treatment of WHIM Syndrome. Reply.

McDermott DH, Murphy PM.

N Engl J Med. 2019 Apr 18;380(16):e25. doi: 10.1056/NEJMc1901646. No abstract available.

PMID:
30995388
7.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.

PMID:
30968729
8.

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF.

J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.

9.

Ambivalent Homoprejudice towards Gay Men: Theory Development and Validation.

Brooks AS, Luyt R, Zawisza M, McDermott DT.

J Homosex. 2019 Mar 18:1-29. doi: 10.1080/00918369.2019.1585729. [Epub ahead of print]

PMID:
30880630
10.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

11.

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.

Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, Rao S, McDermott DF.

Immunotherapy. 2019 May;11(7):617-629. doi: 10.2217/imt-2018-0208. Epub 2019 Mar 11.

12.

Well-Being Among Older Gay and Bisexual Men and Women in England: A Cross-sectional Population Study.

Grabovac I, Smith L, McDermott DT, Stefanac S, Yang L, Veronese N, Jackson SE.

J Am Med Dir Assoc. 2019 Feb 28. pii: S1525-8610(19)30146-X. doi: 10.1016/j.jamda.2019.01.119. [Epub ahead of print]

PMID:
30827893
13.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

14.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
15.

Tumor Cavity Recurrence after Stereotactic Radiosurgery of Surgically Resected Brain Metastases: Implication of Deviations from Contouring Guidelines.

McDermott DM, Hack JD, Cifarelli CP, Vargo JA.

Stereotact Funct Neurosurg. 2019;97(1):24-30. doi: 10.1159/000496156. Epub 2019 Feb 14.

PMID:
30763944
16.

Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status.

Duff K, McDermott D, Luong D, Randolph C, Boxer AL.

J Clin Exp Neuropsychol. 2019 Jul;41(5):469-475. doi: 10.1080/13803395.2019.1572073. Epub 2019 Feb 4.

PMID:
30712468
17.

Power, Process and Context in Theory Based Evaluation of Policy Implementation: A Response to Recent Commentaries.

Lawless A, Baum F, Delany T, MacDougall C, Williams C, McDermott D, van Eyk H.

Int J Health Policy Manag. 2018 Nov 11;8(1):61-62. doi: 10.15171/ijhpm.2018.109. No abstract available.

18.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.

Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.

PMID:
30670497
19.

Plerixafor for the Treatment of WHIM Syndrome.

McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM.

N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575.

PMID:
30625055
20.

WHIM syndrome: Immunopathogenesis, treatment and cure strategies.

McDermott DH, Murphy PM.

Immunol Rev. 2019 Jan;287(1):91-102. doi: 10.1111/imr.12719. Review.

PMID:
30565238
21.

Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.

Tarhini A, McDermott D, Ambavane A, Gupte-Singh K, Aponte-Ribero V, Ritchings C, Benedict A, Rao S, Regan MM, Atkins M.

Immunotherapy. 2019 Mar;11(4):283-295. doi: 10.2217/imt-2018-0168. Epub 2018 Dec 19.

22.

Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency.

Pastrana DV, Peretti A, Welch NL, Borgogna C, Olivero C, Badolato R, Notarangelo LD, Gariglio M, FitzGerald PC, McIntosh CE, Reeves J, Starrett GJ, Bliskovsky V, Velez D, Brownell I, Yarchoan R, Wyvill KM, Uldrick TS, Maldarelli F, Lisco A, Sereti I, Gonzalez CM, Androphy EJ, McBride AA, Van Doorslaer K, Garcia F, Dvoretzky I, Liu JS, Han J, Murphy PM, McDermott DH, Buck CB.

mSphere. 2018 Dec 12;3(6). pii: e00645-18. doi: 10.1128/mSphereDirect.00645-18.

23.

Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery.

McDermott DF, Carducci M.

J Clin Oncol. 2018 Oct 29:JCO1801198. doi: 10.1200/JCO.18.01198. [Epub ahead of print] No abstract available.

PMID:
30372393
24.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

25.

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM.

Cancer. 2018 Nov 15;124(22):4332-4341. doi: 10.1002/cncr.31734. Epub 2018 Oct 10.

PMID:
30303516
26.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
27.

Qualitative protocol for understanding the contribution of Australian policy in the urban planning, justice, energy and environment sectors to promoting health and health equity.

Baum F, Delany-Crowe T, Fisher M, MacDougall C, Harris P, McDermott D, Marinova D.

BMJ Open. 2018 Oct 4;8(9):e025358. doi: 10.1136/bmjopen-2018-025358.

28.

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.

Hamieh L, Choueiri TK, Ogórek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, Agarwal N, Gao W, Signoretti S, Kwiatkowski DJ.

PLoS Genet. 2018 Sep 26;14(9):e1007679. doi: 10.1371/journal.pgen.1007679. eCollection 2018 Sep.

29.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.

PMID:
30211813
30.

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231 Study Group; PROPSPERA investigators; 4RNTI-1authors; Tau Restoration on PSP (TAUROS) Investigators.

Parkinsonism Relat Disord. 2019 Mar;60:138-145. doi: 10.1016/j.parkreldis.2018.08.025. Epub 2018 Sep 4.

PMID:
30201421
31.

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M.

Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.

PMID:
30191365
32.

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP.

Oncologist. 2019 Feb;24(2):202-210. doi: 10.1634/theoncologist.2018-0299. Epub 2018 Sep 6.

PMID:
30190302
33.

Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, Sabater J, Ritchings C, Aponte-Ribero V, Regan MM, Atkins M.

Immunotherapy. 2018 Oct;10(14):1241-1252. doi: 10.2217/imt-2018-0085. Epub 2018 Sep 3.

34.

Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.

Tan SY, Najita J, Li X, Strazzulla LC, Dunbar H, Lee MY, Seery VJ, Buchbinder EI, Tawa NE, McDermott DF, Lee SJ, Atkins MB, Kim CC.

Melanoma Res. 2019 Feb;29(1):70-76. doi: 10.1097/CMR.0000000000000483.

PMID:
30169431
35.

Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.

Gao X, McDermott DF.

Expert Opin Biol Ther. 2018 Sep;18(9):947-957. doi: 10.1080/14712598.2018.1513485. Epub 2018 Aug 30. Review.

PMID:
30124333
36.

Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Gao X, McDermott DF.

Cancer J. 2018 Jul/Aug;24(4):171-179. doi: 10.1097/PPO.0000000000000323. Review.

PMID:
30119080
37.

Supporting the Quality of Measurement and Evaluation in Education.

Mason DL, Wentling WA 2nd, Englert NC, George L, Hampe HM, Hellier S, Kaufmann JA, Locasto LW, McDermott DS.

J Nucl Med Technol. 2018 Dec;46(4):384-390. doi: 10.2967/jnmt.118.210385. Epub 2018 Aug 3.

PMID:
30076250
38.

Developing a Framework for a Program Theory-Based Approach to Evaluating Policy Processes and Outcomes: Health in All Policies in South Australia.

Lawless A, Baum F, Delany-Crowe T, MacDougall C, Williams C, McDermott D, Eyk HV.

Int J Health Policy Manag. 2017 Oct 22;7(6):510-521. doi: 10.15171/ijhpm.2017.121.

39.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29867230
40.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

41.

A Batf3/Nlrp3/IL-18 Axis Promotes Natural Killer Cell IL-10 Production during Listeria monocytogenes Infection.

Clark SE, Schmidt RL, McDermott DS, Lenz LL.

Cell Rep. 2018 May 29;23(9):2582-2594. doi: 10.1016/j.celrep.2018.04.106.

42.

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Gao X, Jegede O, Gray C, Catalano PJ, Novak J, Kwiatkowski DJ, McKay RR, George DJ, Choueiri TK, McDermott DF, Signoretti S, Bhatt RS.

Clin Genitourin Cancer. 2018 Oct;16(5):341-348. doi: 10.1016/j.clgc.2018.04.001. Epub 2018 Apr 25.

PMID:
29754934
43.

Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.

Gao JL, Yim E, Siwicki M, Yang A, Liu Q, Azani A, Owusu-Ansah A, McDermott DH, Murphy PM.

J Clin Invest. 2018 Aug 1;128(8):3312-3318. doi: 10.1172/JCI120375. Epub 2018 Jun 25.

44.

Understanding Australian policies on public health using social and political science theories: reflections from an Academy of the Social Sciences in Australia Workshop.

Baum F, Graycar A, Delany-Crowe T, de Leeuw E, Bacchi C, Popay J, Orchard L, Colebatch H, Friel S, MacDougall C, Harris E, Lawless A, McDermott D, Fisher M, Harris P, Phillips C, Fitzgerald J.

Health Promot Int. 2018 Apr 19. doi: 10.1093/heapro/day014. [Epub ahead of print]

PMID:
29684128
45.

The priming function of in-car audio instruction.

Keyes H, Whitmore A, Naneva S, McDermott D.

Q J Exp Psychol (Hove). 2019 Mar;72(3):643-650. doi: 10.1177/1747021818773293. Epub 2018 May 10.

PMID:
29649945
46.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

47.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

PMID:
29530667
48.

Polistes metricus queens exhibit personality variation and behavioral syndromes.

Wright CM, Hyland TD, Izzo AS, McDermott DR, Tibbetts EA, Pruitt JN.

Curr Zool. 2018 Feb;64(1):45-52. doi: 10.1093/cz/zox008. Epub 2017 Mar 8.

49.

Description, Normative Data, and Utility of the Hearing Aid Skills and Knowledge Test.

Saunders GH, Morse-Fortier C, McDermott DJ, Vachhani JJ, Grush LD, Griest S, Lewis MS.

J Am Acad Audiol. 2018 Mar;29(3):233-242. doi: 10.3766/jaaa.16153.

PMID:
29488873
50.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

Supplemental Content

Loading ...
Support Center